Results 131 to 140 of about 178,280 (162)
Some of the next articles are maybe not open access.
Autoimmunity in ocular and generalised myasthenia gravis
Journal of Neuroimmunology, 1981Restricted ocular myasthenia gravis (OMG) and generalised myasthenia gravis (GMG) have been shown to differ in a number of respects. In OMG, antiacetylcholine receptor, antistriational and antinuclear antibodies were rare relative to their frequency in GMG. In contrast, antithyroid antibodies and a history of thyroid disease were much more prevalent in
M J, Garlepp +8 more
openaire +2 more sources
Therapeutic options in ocular myasthenia gravis
Neuromuscular Disorders, 2001The term ocular myasthenia gravis refers to the disease clinically restricted to extrinsic ocular muscles. It can be disabling as ptosis, and to a greater extent diplopia, both interfere with daily activities. Although ocular disturbances are the most frequent initial complaints in myasthenic patients, symptoms usually progress to generalized disease ...
A, Evoli +4 more
openaire +2 more sources
Journal of the National Medical Association, 1994
Ocular dysfunction accounts for nearly 70% of the initial manifestations of myasthenia gravis. Since the prevalence rate of myasthenia gravis is two to 10 cases per 100,000 population, it is important for clinicians to be cognizant of this disorder and its varied ocular presentations.
G A, March, L N, Johnson
openaire +1 more source
Ocular dysfunction accounts for nearly 70% of the initial manifestations of myasthenia gravis. Since the prevalence rate of myasthenia gravis is two to 10 cases per 100,000 population, it is important for clinicians to be cognizant of this disorder and its varied ocular presentations.
G A, March, L N, Johnson
openaire +1 more source
Ptosis Repair in Ocular Myasthenia Gravis
Seminars in Ophthalmology, 2016Ptosis repair was performed in patients with ocular myasthenia gravis by a posterior approach (Fasanella-Servat, 12 eyelids of nine patients) or levator advancement (eight eyelids of five patients) techniques. There were eight males and five females. Median age was 73 years and range 30-86 years. The median duration of myasthenia was 10 years and range
Michel J, Belliveau +1 more
openaire +2 more sources
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2013
Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to provide a pragmatic approach to the pathogenesis, clinical features, diagnostics and therapeutic strategies in the clinical routine.
S, Pitz, B, Jordan, S, Zierz
openaire +1 more source
Ocular myasthenia gravis, although clinically often characterized by typical classical features, can cause considerable diagnostic problems. This article aims to provide a pragmatic approach to the pathogenesis, clinical features, diagnostics and therapeutic strategies in the clinical routine.
S, Pitz, B, Jordan, S, Zierz
openaire +1 more source
Myasthenia Gravis: Systemic and Ocular Considerations
Ophthalmology, 1979In the early 1930s, the neuromuscular junction was identified as the site of the abnormality in myasthenia gravis, based on the response of patients to anticholinesterase medication.3 It has since become apparent that acetylcholine, the natural transmitter, is synthesized chiefly in the motor nerve terminals4 and is stored in vesicles for subsequent ...
openaire +2 more sources
Peribulbar Corticosteroids for Ocular Myasthenia Gravis
Journal of Neuro-OphthalmologyBackground: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid ...
Rachel Lasry +2 more
openaire +2 more sources
Ocular Response to Corticotropin in Myasthenia Gravis
Archives of Ophthalmology, 1973Twenty-two patients who had myasthenia gravis with ptosis, ophthalmoparesis, or both, were treated with massive doses of corticotropin (adrenocorticotrophic hormone). The ocular symptoms in eight of the patients improved significantly. Subsequently, four patients who failed to improve with corticotropin therapy had thymectomies, followed by ...
openaire +2 more sources